The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
Status:
Completed
Trial end date:
2018-01-28
Target enrollment:
Participant gender:
Summary
This is an open-label, single arm study to explore whether 18F-ALF-NOTA-PRGD2 PET/CT scan can
predict the efficacy and adverse events of apatinib in patients with malignancies.
Integrin αvβ3 has been shown to play an important role in angiogenesis and up-regulated
obviously in various types of tumor cells and activated endothelial cells. The
arginine-glycine-aspartic acid (RGD) tripeptide sequence can bind to integrin αvβ3 with high
affinity and specificity. The 18F-ALF-NOTA-PRGD2 will highly combine with αvβ3, and thus will
monitor the antiangiogenic status.In the current study, investigators propose to evaluate the
feasibility of 18F-RGD PET/CT in monitoring efficacy and adverse events of apatinib in
malignancies.